<DOC>
	<DOCNO>NCT00532545</DOCNO>
	<brief_summary>To test hypothesis Teriparatide injection give 20 micrograms/daily subcutaneously , one month , able produce reliable change bone marker severe osteoporotic population</brief_summary>
	<brief_title>Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Presents severe osteoporosis base disease diagnostic criterion upon physician assessment Postmenopausal , nonpregnant , woman older 50 year age , previous fracture history hip , spine , wrist , rib , clavicle , humerus , tibia , fibula men 50 year age low impact fracture ( fragility ) . Outpatients without concomitant disease life expectancy least 3 year , accord medical criterion . Can medicine disturb bone metabolism . Patients capable selfinjection , learn use Pen device agreement use . Directly affiliated conduct study , immediate family someone directly affiliate conduct study ( , Lilly employee , investigator , site personnel , immediate family ) . Immediate family define spouse , parent , child , sibling , whether biological legally adopt . Received treatment within last 30 day drug ( include study drug ) receive regulatory approval indication time study entry . Previously complete withdrawn study study investigate Teriparatide . Secondary osteoporosis disease affect bone metabolism , renal osteodystrophy , osteomalacia , hypoparathyroidism , hyperparathyroidism , intestinal malabsorption . Cancer history 5 year prior visit 1 , exemption basocellular carcinoma treat cervix carcinoma definitively treat least 1 year visit 1</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>